CC
Commodore Capital Portfolio holdings
AUM
$1.42B
This Quarter Return
+51.9%
1 Year Return
+73.3%
3 Year Return
+1,330.82%
5 Year Return
–
10 Year Return
–
AUM
$1.5B
AUM Growth
+$1.5B
(+31%)
Cap. Flow
-$130M
Cap. Flow
% of AUM
-8.68%
Top 10 Holdings %
Top 10 Hldgs %
60.18%
Holding
43
New
11
Increased
11
Reduced
12
Closed
4
Top Buys
| 1 |
MindMed
MNMD
|
$54.8M |
| 2 |
Oric Pharmaceuticals
ORIC
|
$27.5M |
| 3 |
Perspective Therapeutics
CATX
|
$25.1M |
| 4 |
Kyverna Therapeutics
KYTX
|
$22.7M |
| 5 |
Pharvaris
PHVS
|
$21.4M |
Top Sells
| 1 |
Adverum Biotechnologies
ADVM
|
$132M |
| 2 |
Vera Therapeutics
VERA
|
$98.5M |
| 3 |
RYZB
RayzeBio, Inc. Common Stock
RYZB
|
$23.9M |
| 4 |
Soleno Therapeutics
SLNO
|
$22.7M |
| 5 |
Rhythm Pharmaceuticals
RYTM
|
$21.7M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Merus
MRUS
$4.98B
| $196M | 13.13% |
4,360,000
-387,373
| -8% | -$17.4M |
|
|
2
Vera Therapeutics
VERA
$1.38B
| $136M | 9.13% |
3,165,000
-2,285,000
| -42% | -$98.5M |
|
3
Nuvalent
NUVL
$5.52B
| $112M | 7.47% |
1,487,756
+156,719
| +12% | +$11.8M |
|
4
Xenon Pharmaceuticals
XENE
$2.98B
| $93.3M | 6.24% |
2,167,793
| – | – |
|
5
Spyre Therapeutics
SYRE
$996M
| $71.5M | 4.78% |
1,884,084
| – | – |
|
6
Enliven Therapeutics
ELVN
$1.2B
| $69.9M | 4.67% |
3,973,245
+1,071,429
| +37% | +$18.8M |
|
7
Vaxcyte
PCVX
$4B
| $58.7M | 3.93% |
860,000
-240,000
| -22% | -$16.4M |
|
|
8
MindMed
MNMD
$676M
| $54.8M | 3.67% |
+5,833,333
| New | +$54.8M |
|
|
ALPN
9
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $54.5M | 3.64% |
1,375,000
-235,000
| -15% | -$9.32M |
|
10
Arvinas
ARVN
$568M
| $52.6M | 3.52% |
1,275,000
+275,000
| +28% | +$11.4M |
|
|
11
Rhythm Pharmaceuticals
RYTM
$6.85B
| $45.5M | 3.04% |
1,050,000
-500,000
| -32% | -$21.7M |
|
12
Cogent Biosciences
COGT
$1.69B
| $43.2M | 2.89% |
6,425,000
+858,974
| +15% | +$5.77M |
|
|
13
Pharvaris
PHVS
$1.39B
| $39.9M | 2.67% |
1,725,000
+925,000
| +116% | +$21.4M |
|
14
Celldex Therapeutics
CLDX
$1.47B
| $36.4M | 2.43% |
866,468
+164,501
| +23% | +$6.9M |
|
15
Nkarta
NKTX
$151M
| $34.2M | 2.29% |
3,165,000
+435,000
| +16% | +$4.7M |
|
16
Viridian Therapeutics
VRDN
$1.5B
| $33.9M | 2.27% |
1,934,653
+10,579
| +0.5% | +$185K |
|
17
Celcuity
CELC
$2.17B
| $33.6M | 2.25% |
1,555,954
-198,750
| -11% | -$4.29M |
|
18
Kura Oncology
KURA
$686M
| $32.5M | 2.18% |
1,525,000
+276,938
| +22% | +$5.91M |
|
19
C4 Therapeutics
CCCC
$185M
| $27.9M | 1.86% |
3,410,384
-389,616
| -10% | -$3.18M |
|
|
20
Oric Pharmaceuticals
ORIC
$994M
| $27.5M | 1.84% |
+2,000,000
| New | +$27.5M |
|
|
ABVX
21
Abivax
ABVX
$6.12B
| $27.1M | 1.81% |
1,895,003
| – | – |
|
|
22
Perspective Therapeutics
CATX
$250M
| $25.1M | 1.68% |
+21,052,631
| New | +$25.1M |
|
23
Immunovant
IMVT
$2.56B
| $24.3M | 1.62% |
750,990
-249,010
| -25% | -$8.05M |
|
|
24
Kyverna Therapeutics
KYTX
$160M
| $22.7M | 1.52% |
+912,189
| New | +$22.7M |
|
25
enGene Holdings
ENGN
$236M
| $21.2M | 1.42% |
+1,250,000
| New | +$21.2M |
|